Status:
COMPLETED
Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Conditions:
Cervix Lesion
Cervical Cancer
Eligibility:
FEMALE
18-99 years
Brief Summary
The purpose of this study is to see if circulating HPV DNA (cHPVDNA) can be used as a noninvasive biomarker for cervical intraepithelial neoplasia (CIN) 2-3 in hopes of reducing procedures and costs f...
Detailed Description
cHPVDNA is detectable in plasma of patients with invasive disease and CIN 1-3, and with the development of a highly sensitive and specific droplet digital Polymerase Chain Reaction (PCR) assay, it is ...
Eligibility Criteria
Inclusion
- No history of previously treated cervical cancer
- Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee
Exclusion
- Women who are pregnant or nursing
Key Trial Info
Start Date :
February 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2024
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT04274465
Start Date
February 26 2020
End Date
July 15 2024
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tuvara Jenene King
Chapel Hill, North Carolina, United States, 27599